p97 ATPase Inhibitors for Cancer and Neurodegneration

Search text

About 24 results

(0.10 seconds)

HDAC Inhibitors as Anticancer Agents

05372

University of Pittsburgh researchers have developed a series of chromane-based hydroxamic acids that have been demonstrated to be potent and selective HDAC inhibitors with potential use as novel anticancer and anti-neurodegenerative agents.

· Entirely novel set of histone deacetylase inhibitors.

, Topacio, A. Z., Sannino, S., Brodsky, J. L., & Wipf, P.

2020-05-19

NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties

05522

University of Pittsburgh researchers have synthesized and tested a novel class of Nampt inhibitors in a current study, which shows that they have exhibited excellent potency and ADME properties.

· Nampt inhibitors show excellent ADME properties.

Therapeutic Modality

Small Molecule

Immunology Oncology

Autoimmune Immuno-oncology Small molecule

Beibei Chen

Med-Medicine

2020-10-06

Glutaminase Inhibitors

03304

Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.

” Inhibition of glutaminase through antisense, siRNA, and small molecule inhibitors has been shown to lead to a reduction in tumor cell proliferation as well as tumor size reduction in mice and is a promising approach to fighting cancer.

A novel series of small molecule inhibitors of kidney-type glutaminase was designed and synthesized.

Pharm-Pharmaceutical Science

2014-04-29